Immunoscience portfolio Orencia, Bristol-Myers Squibb’s (BMY) only immunoscience product, is a fusion protein approved for the treatment of moderate-to-severe rheumatoid arthritis and related issues. The drug prevents further damage to bones and joints. Orencia revenue The above chart compares Orencia sales over the last few quarters. Orencia recorded revenue of $632 million in 3Q17, a growth […]
The consumer segment Johnson & Johnson’s (JNJ) consumer segment reported revenue of $3.5 billion in 2Q17, a growth of 1.7% from the revenue of $3.4 billion reported in 2Q16. This figure includes 2.3% growth in operating revenue, and was partially offset by a 0.6% foreign exchange impact. Baby care franchise The baby care franchise reported revenue […]
Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets.
We discussed the products that contribute to the growth of Pfizer’s (PFE) revenues in 2Q17. Let’s now take a look at the products that have impacted revenue growth in 2Q17.
As of July 31, 2017, of the 22 analysts tracking Pfizer, ten recommend a “buy” for the stock, while 11 recommend a “hold,” and one recommends a “sell.”
Analysts expect Bristol-Myers Squibb’s (BMY) top line to rise 4.4% to ~$5.1 billion in 2Q17. They expect its earnings per share to be $0.74 in the quarter.
Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment grew ~4.9% to ~$6.7 billion for 2Q17, compared with $6.4 billion in 2Q16. This rise included an operational increase of 5.9%, and was offset by a 1% impact of foreign exchange. Cardiovascular care franchise Cardiovascular care franchise sales rose 11.3% to $523 million for 2Q17. This […]
Johnson & Johnson’s (JNJ) Medical Devices segment deals with the vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care franchises.
A look at Pfizer Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer’s portfolio, which comprises the Innovative Health and Essential Health segments, includes various medicines, vaccines, and consumer healthcare products. Stock price performance Pfizer’s stock price has fallen ~2.6% in 2Q17. However, the stock price had risen ~2.3% year-to-date as of July […]
Tanezumab is an investigational drug co-developed by Pfizer (PFE) and Eli Lilly (LLY) for pain management in chronic pain related to cancer, lower back pain, and osteoarthritis.
Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.
Volanesorsen Ionis Pharmaceuticals’s (IONS) volanesorsen is a drug designed to reduce apolipoprotein C-III production and triglycerides in patients with dyslipidemia. Akcea Therapeutics, a wholly owned subsidiary of Ionis, is engaged in pre-commercialization activities for volanesorsen, and will take care of the drug’s commercialization once it is approved by the FDA and the European Commission. The […]
Johnson & Johnson’s (JNJ) consumer segment includes the baby care, beauty products, oral care, over-the-counter, women’s health, and wound care franchises.
Foreign exchange rates have had a constant negative impact on JNJ’s growth rate in each quarter, mainly because nearly 48% of its total revenue is reported from sales outside the United States.
The Virology segment was Bristol-Myers Squibb’s (BMY) second-largest revenue contributor in 2016. The segment contributed ~24.4% of BMY’s total revenue in the year.
Eli Lilly stock has fallen 7.5% in the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~12% over the next 12 months.
Johnson & Johnson’s (JNJ) consumer healthcare segment includes baby care, oral care, skin care, over-the-counter products, women’s health, and wound care franchises.
Januvia and Janumet are two blockbuster drugs in Merck’s diabetes franchise. These drugs help lower blood sugar level in patients with type-2 diabetes.
Pfizer saw a 2% rise in Lyrica revenues at $1.24 billion in 3Q16, as compared to $1.22 billion in 3Q15, primarily due to a 12% rise in sales in US markets.
Pfizer reported an ~8% rise in its top line in its 3Q16 earnings on November 1,surpassing analysts’ estimates for revenues but missing estimates for EPS.
PE multiples are widely available and represent what one share can buy for an equity investor. On October 26, 2016, Merck (MRK) was trading at a forward PE multiple of ~16.0x.
Merck & Co. (MRK) has seen the negative revenue impact of lower sales levels for a few of its blockbuster drugs, including Remicade, Cubicin, Zetia, and Vytorin.
The Consumer segment Johnson & Johnson’s (JNJ) Consumer segment’s revenue fell 1.6% to $3.3 billion between 3Q15 and 3Q16. This fall is due to an operational growth of 0.1%, which was more than offset by a negative currency impact of 1.7%. The currency devaluation in Venezuela impacted worldwide growth by ~1.1% during 3Q16. Baby care […]
Johnson & Johnson’s growth rate As discussed in the previous part of this series, on a constant-currency basis, Johnson & Johnson (JNJ) reported a ~4.3% revenue rise between 3Q15 and 3Q16. The company’s 3Q16 revenue was $17.8 billion, surpassing analysts’ estimate of $17.7 billion. The above graph shows that foreign exchange rates have had a […]
Johnson & Johnson’s (JNJ) Consumer Healthcare segment includes baby care, oral care, skin care, over-the-counter products, women’s health, and wound care.
Merck is now focused on developing new products as well as expanding the labels of its existing products. Let’s look at its recent corporate and R&D progress.
Revenue growth drivers Previously we discussed Pfizer’s (PFE) revenues and growth trends. To better understand the factors affecting growth, let’s now explore Pfizer’s product portfolio and pipeline. The key performers in the product portfolio include Lyrica, Ibrance, Xeljanz, and Eliquis from the Innovative Health business. Products with positive growth There were several products that contributed […]
Analysts expect Pfizer’s (PFE) 2Q16 revenue to grow ~9.8% to ~$13.0 billion following an increase in the sales of the Prevnar family and the company’s new drugs Xalkori and Xeljanz, among others.
